A Study of Novel Study Interventions and Combinations in Participants With Colorectal Cancer

The main purpose of this study is to evaluate the safety and efficacy of novel study interventions and combinations in participants with Colorectal Cancer (CRC).

Trial Details

NCT ID

NCT06792695

Phase

PHASE2

Sponsor

AstraZeneca

Status

RECRUITING

Cancer Type

Colorectal Cancer

Interventions

Volrustomig
FOLFIRI (Fluorouracil (5-FU), leucovorin, irinotecan)
Bevacizumab

Locations (sample)

Scottsdale, Arizona, United States|33.50921,-111.89903
Los Angeles, California, United States|34.05223,-118.24368
Washington D.C., District of Columbia, United States|38.89511,-77.03637
Chicago, Illinois, United States|41.85003,-87.65005
Baltimore, Maryland, United States|39.29038,-76.61219

Key Eligibility Criteria

Histopathologically confirmed colorectal adenocarcinoma.
Provision of FFPE tumor sample collected as per SoC.
Presence of measurable disease by RECIST 1.1 criteria.
ECOG performance status of 0 or 1.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Colorectal Cancer Trials on Trialify →